Telmoliv AMH Tablet is a fixed-dose combination medication formulated to effectively manage essential hypertension in patients requiring a three-drug regimen. It combines three potent antihypertensive agents—Telmisartan, Amlodipine, and Hydrochlorothiazide—that act through complementary mechanisms to provide sustained blood pressure control and reduce the risk of cardiovascular events.
Telmisartan (40 mg) is an angiotensin II receptor blocker (ARB) that inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, promoting blood vessel relaxation and lowering blood pressure.
Amlodipine (5 mg) is a calcium channel blocker that relaxes the smooth muscles of the heart and blood vessels, improving blood flow and reducing pressure.
Hydrochlorothiazide (12.5 mg) is a thiazide diuretic that reduces blood pressure by promoting the excretion of excess sodium and water through urine, which decreases blood volume and vascular resistance.
This triple-action approach helps patients who do not respond adequately to single or dual therapy and are at risk for stroke, heart attack, or kidney damage due to persistent high blood pressure. By controlling blood pressure over 24 hours, Telmoliv AMH Tablet offers both therapeutic efficacy and patient convenience with once-daily dosing.
Patients should take the tablet daily at the same time, with or without food. Lifestyle modifications such as reducing salt intake, regular exercise, weight control, and avoiding alcohol and tobacco use are recommended to support therapy.
This medication is especially beneficial in individuals with comorbidities such as left ventricular hypertrophy, diabetes, or early-stage renal dysfunction, as its components provide renal and cardiovascular protection.
